TABLE 1

Tissue-to-plasma concentration ratio in β-phase (Kp,β) of [14C]GPFX in mrp1(–/–) and mrp1(+/+) mice

Tissue
[14C]GPFX, Kp,β (ml/g)a
mrp1(-/-)
mrp1(+/+)
Blood Cell 0.752 ± 0.120 0.723 ± 0.076
CSF 0.431 ± 0.072 0.652 ± 0.221
Brain 0.850 ± 0.064 0.875 ± 0.049
Trachea 8.50 ± 0.85* 5.92 ± 0.61
Lung 20.8 ± 2.8 18.3 ± 2.4
Thymus 14.0 ± 1.3 12.5 ± 1.1
Heart 6.25 ± 0.36* 4.63 ± 0.20
Kidney 19.2 ± 1.5* 13.7 ± 0.7
Spleen 25.9 ± 1.2* 17.1 ± 1.2
Pancreas 19.3 ± 1.9 17.2 ± 1.1
Testis 17.7 ± 1.5 15.8 ± 1.0
Fat 1.44 ± 0.25 1.55 ± 0.34
Muscle 3.67 ± 0.27 3.66 ± 0.47
Brown Fat 12.7 ± 1.2* 7.99 ± 0.57
Liver 17.8 ± 1.6 17.1 ± 1.4
Stomach 7.53 ± 0.64 6.87 ± 0.82
Small intestine 17.4 ± 1.8 13.6 ± 3.4
Large intestine 31.7 ± 5.4 32.7 ± 5.4
Duodenum 5.57 ± 1.01 7.92 ± 2.70
Jejunum 6.75 ± 1.24 4.92 ± 0.95
Ileum
11.0 ± 3.7
8.46 ± 1.22

  • ↵ a Kp,β was determined from tissue distributions at 4 to 6 h after an intravenous injection of [14C]GPFX at a dose of 5 mg/kg. Each value represents the mean ± S.E. of 6 to 12 mice in GPFX.

  • ↵* P < 0.05 significantly different from mrp1 (+/+).